Emergent BioSolutions’ COVID-19 Human Immune Globulin Product Candidate to be Included in NIH-Sponsored Phase 3 Clinical Trial of Hyperimmune Intravenous Immunoglobulin to Treat COVID-19

NEXT STORY
Saniona receives pre-IND feedback from FDA on regulatory path for Tesomet in Prader-Willi Syndrome (PWS) and Hypothalamic Obesity (HO)
PREV STORY
American Gene Technologies to Present at 2020 Virtual Cell & Gene Meeting on the Mesa
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Sanofi: Dupixent® (dupilumab) showed positive topline results in two Phase 3 trials of patients with chronic rhinosinusitis with nasal polyps

Dupixent® (dupilumab) showed positive topline results in two Phase 3 trials of patients with ...

author_avatar
NASDAQ Market News

Q3 2019 financial information and update on the partnership with Boehringer Ingelheim

author_avatar
NASDAQ Market News

Medistar Corporation and Voyages Behavioral Health Announce Development of a Behavioral Health Hospital in Pensacola

author_avatar
NASDAQ Market News